Literature DB >> 24464715

LY2605541--a preferential hepato-specific insulin analogue.

Sten Madsbad1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24464715     DOI: 10.2337/db13-1646

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


× No keyword cloud information.
  6 in total

1.  Trehalose Glycopolymer Enhances Both Solution Stability and Pharmacokinetics of a Therapeutic Protein.

Authors:  Yang Liu; Juneyoung Lee; Kathryn M Mansfield; Jeong Hoon Ko; Sahar Sallam; Chrys Wesdemiotis; Heather D Maynard
Journal:  Bioconjug Chem       Date:  2017-01-03       Impact factor: 4.774

Review 2.  Tissue barriers and novel approaches to achieve hepatoselectivity of subcutaneously-injected insulin therapeutics.

Authors:  Juntang Shao; Jennica L Zaro; Wei-Chiang Shen
Journal:  Tissue Barriers       Date:  2016-03-04

3.  AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients.

Authors:  Allegra Kaufman; Lubna Abuqayyas; William S Denney; Erik J Tillman; Tim Rolph
Journal:  Cell Rep Med       Date:  2020-07-21

4.  Structural Perspectives of Insulin Receptor Isoform-Selective Insulin Analogs.

Authors:  Jiří Jiráček; Lenka Žáková
Journal:  Front Endocrinol (Lausanne)       Date:  2017-07-27       Impact factor: 5.555

Review 5.  How Can a Good Idea Fail? Basal Insulin Peglispro [LY2605541] for the Treatment of Type 2 Diabetes.

Authors:  Araceli Muñoz-Garach; María Molina-Vega; Francisco J Tinahones
Journal:  Diabetes Ther       Date:  2016-11-28       Impact factor: 2.945

6.  Role of Emerging Insulin Technologies in the Initiation and Intensification of Insulin Therapy for Diabetes in Primary Care.

Authors:  Stephen A Brunton; Davida F Kruger; Martha M Funnell
Journal:  Clin Diabetes       Date:  2016-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.